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ABSTRACT 
Objective: The presence of tight junctions in blood-brain barrier creates a major problem for the delivery of drugs and severely affects adequate 
therapeutic concentration to reach the brain. For the treatment of epilepsy, oral route of administration is most convenient but shows delayed 
absorption. Moreover, in emergency cases, parenteral administration is not possible as it requires medical assistance. Thus, an alternative route of 
drug delivery is highly desirable for an effective outcome.  
Methods: In the present study, bioadhesive chitosan nanoparticles of topiramate for intranasal administration were prepared by ionotropic 
gelation method using chitosan as bioadhesive polymer and sodium tripolyphosphate as the crosslinking agent. The prepared nanoparticles were 
evaluated for physicochemical properties like particle size, surface morphology, drug content, entrapment efficiency, thermal behavior and 
crystallinity, in vitro drug diffusion, ex vivo bio adhesion, and ex vivo biocompatibility studies in excised sheep nasal mucosa.  
Results: Differential scanning calorimetry and x-ray diffraction study showed molecular dispersion of drug into the polymer matrices and 
conversion of it into an amorphous form. Nanoparticles obtained were discrete in nature (size 313.5 nm) and appropriate for intranasal 
administration. The topiramate nanoparticles revealed high encapsulation efficacy, strong bioadhesion potential and high ex vivo permeation and 
did not exhibit any deformity to the nasal mucosa. In vitro drug diffusion of optimized formulation showed 92.91% release of drugs after 180 min. 
Ex-vivo permeation of drugs across nasal mucosa was 89.03 % after 180 min.  
Conclusion: Hence, the intranasal administration of topiramate using chitosan can be a promising alternative for brain targeting and the treatment 
of epilepsy. 
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INTRODUCTION 
Epilepsy is a chronic neurological disorder characterized by recurrent 
seizures or periods of unusual behaviour, and sometimes loss of 
consciousness [1, 2]. Although, oral route of administration is most 
convenient for the treatment of epilepsy, has an insignificant role in 
the treatment of acute epileptic attack due to delayed absorption when 
given orally. Moreover, in emergency cases, parenteral administration 
is not possible as it requires medical assistance. Thus, an alternative 
route of drug delivery is highly desirable for effective outcomes [3, 4].  
Intranasal route provides greater surface area for absorption of drugs 
along with porous and highly vascularised epithelial layer. The total 
blood flow to the nasal site is also greater that facilitates faster drug 
absorption and hence faster onset of action. Beside this intranasal 
administration also facilitates the transport of centrally acting drugs 
through the olfactory region and trigeminal nerves deliver drugs rapidly 
and efficiently to the brain [5]. Hence it is a convenient and suitable route 
of administration in the treatment of epilepsy [6]. 
On the other hand, mucociliary clearance is the limiting factor that 
decreases the residing time of drug in the nasal cavity, thereby limits 
the extent of drug absorption [7]. The limitation of mucociliary 
clearance can be overcome by formulating a dosage form with a 
mucoadhesive agent. Adhesion of formulation to the mucosal 
membrane will prevent the drug from early removal out of the nasal 
cavity and will provide greater time for its absorption to produce a 
sufficient therapeutic level [8, 9]. 
In this context chitosan, a natural polysaccharide having a 
biodegradable, biocompatible, non-toxic and mucoadhesive property 
is been chosen as the carrier for the preparation of mucoadhesive 
nanoparticles [10]. Besides, it also enhances the paracellular 
absorption by opening the tight junctions between the epithelial cells 
[11]. Chitosan, being cationic in nature interacts electrostatically with 
negatively charged sialic acid moieties on the mucosal membrane, is 
responsible for its mucoadhesive property [12]. The nanoparticles 
based formulation provides drug release specifically to the site with 
improved absorption and activity. Besides, site-specific delivery 
reduces the side effects of drugs associated with conventional therapy 
[13, 14]. Intranasal formulation of antiepileptic agents with chitosan 
has successfully improved the mucoadhesion, release, and absorption 
of drugs such as lamotrigine and pregabalin [15, 16]. Topiramate is a 
second-generation antiepileptic drug used in partial and generalized 
seizures. It is used as a prophylactic against migraine headaches, 
psychiatric disorders, and obesity. Topiramate is also used in children 
for the treatment of refractory partial seizures with or without 
secondary generalized tonic-clonic seizures [17, 18]. Topiramate is 
only available in oral dosage form and no intranasal formulation is 
been studied (Product information: TOPAMAXTM. Titusville: Janssen 
Pharmaceuticals, Inc.; 2011). Administration of Topiramate with food 
decreases its rate of absorption and it undergoes cytochrome p450 
mediated oxidation [19, 20]. In view of this, the present work was 
designed to formulate bioadhesive nanoparticles of topiramate by 
ionotropic gelation method with chitosan and to carry out its 
characterization. Prepared nanoparticles were evaluated for ex-vivo 
bioadhesion and permeation using sheep nasal mucosa.  
MATERIALS AND METHODS 
Materials 
Chitosan was purchased from Loba Chemie, Mumbai. Topiramate 
was procured from Johnson and Johnson Pharmaceutical Ltd., 
Mumbai. Acetic acid was obtained from Fisher Scientific, Mumbai 
and sodium tripolyphosphate from Hi-Media Laboratories, Mumbai. 
All other reagents used were of analytical reagent grade. 
Preparation of bioadhesive nanoparticles by ionotropic gelation 
method 
Mucoadhesive nanoparticles of topiramate were formulated using 
chitosan and sodium tri-polyphosphate as a crosslinking agent by 
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the ionotropic gelation method. Weighed amount of chitosan and 
drug was dissolved in 2% aqueous acetic acid. To it weighed 
quantity of topiramate was dissolved. Subsequently, 50 ml of the 
polymer solution was added dropwise to the crosslinking solution 
with magnetic stirring (100 rpm) at room temperature. The 
prepared nanoparticles were separated after 30 min, washed with 
deionized water and subsequently dried at 60 °C for 3 h [21]. The 
composition of different formulations is shown in table 1. 
 
Table 1: Composition of topiramate loaded chitosan nanoparticles 
Formulation code Topiramate (mg)  Chitosan (mg) STPP (%) 
F1 100 200 2 
F2 100 200 3 
F3 100 200 4 
F4 100 200 5 
F5 100 225 4 
F6 100 250 4 
F7 100 275 4 
F8 100 300 4 
 
Characterization of nanoparticles 
Particle size and zeta potential  
The optical microscopy method (Motic BMWB microscope) was used 
for evaluating the size and shape of the prepared nanoparticles. A 
small quantity of nanoparticles was dispersed on the slide with the 
help of a small glass rod. The diameters were determined using a 
suitable objective (10X, 40X, 100X). The average particle size of 
nanoparticles can be given by the following formula [22]. 
 
Where n is the number of nanoparticles and d is the size NP. 
Zeta potential determination (surface electric charge) of the 
prepared nanoparticles was carried out by photon correlation 
spectroscopy (PCS) using zeta sizer (Malvern Instruments Ltd, Ver. 
6.2) at 25 °C and a scattering angle of 90 °C, maintaining electric 
field strength of 25 Vm-1. Briefly, weighed amount of nanoparticles 
(5 mg) were dispersed in 10 ml of bidistilled water to get optimum 
100-200 kilo-counts s-1(kcps) for measurement of zeta potential in 
the range of+200 mv to-200 mv [23]. 
Drug content and entrapment efficiency  
The amount of topiramate incorporated into the nanoparticles was 
estimated to determine the drug content and entrapment efficiency 
of the prepared formulations. Nanoparticles equivalent to 10 mg of 
the topiramate were dissolved in 20 ml of pH 6.8 phosphate buffer 
solution and kept overnight to extract the drug from the 
formulation. The solution was then centrifuged (560 rpm) for 10 
min to remove the insoluble content. To the obtained solution, 1 ml 
of ninhydrin solution was added, incubated for 20 min at 70 °C and 
analyzed spectrophotometrically (Analytical Technologies Ltd., 
Gujarat, India) for drug content at 260 nm. The data was collected by 
repeating the procedure in triplicate. Given formula was used for 
calculating drug content entrapment efficiency [24]. 




Where Qp = quantity of drug encapsulated in nanoparticles 





Where E = percentage of encapsulation of nanoparticles 
Qp = quantity of drug encapsulated in nanoparticles 
Qt = quantity of the drug added for encapsulation 
Scanning electron microscopy (SEM) 
To study the shape and surface morphology of prepared topiramate 
nanoparticles, scanning electron microscopy (SEM, JEOL Model JSM-
6390LV) was used. The samples were mounted on a double-
adhesive tape stuck to an aluminum stub. The stubs were coated 
with gold to a thickness of ~300 A ° under an argon atmosphere 
using a gold sputter module in a high-vacuum evaporator. The 
coated samples were then randomly scanned and photomicrographs 
were obtained with SEM [22]. 
Ex-vivo bioadhesion studies 
The ex vivo bioadhesion property of nanoparticles was performed 
on a fresh sheep nasal mucosa. Freshly excised sheep nasal mucosa 
was procured from the local slaughterhouse, cleaned with isotonic 
saline solution and cut into a piece of 2 cm2 for the study. The 
topiramate nanoparticles (100 mg) were applied on the mucosal 
surface and attached on a polyethylene plate. Simulated nasal 
electrolyte solution (100 ml) was poured on nanoparticles. Further, 
it was incubated in desiccators at 90% relative humidity for 15 min 
so as the polymer interact with the membrane. Further, the plate 
was kept at an angle of 45 ° relative to the horizontal plane. 
Phosphate buffer pH 6.8 (37 °C) was peristaltically pumped (5 
ml/min) over the tissue and the perfusate was collected. The 
amount of topiramate in the collected perfusate was estimated after 
1 hour spectrophotometrically. The amount of nanoparticles 
corresponding to the amount of drug in the perfusate was 
determined. The amount of adhered nanoparticles was calculated as 
the difference between the amount of nanoparticles applied and the 
amount of nanoparticles washed off with perfusate. The percent 
mucoadhesion was determined by the given equation [15], 
 
Fourier-transform infrared spectroscopy (FTIR) 
The compatibility studies between topiramate and chitosan were carried 
out by FTIR (Thermo Nicolet, Avatar 370) to detect drug-excipient 
interactions if any. Approximately 2 mg sample was powdered uniformly 
with 200 mg of KBr for the production of KBr compacts. The samples 
were triturated first and then mixed thoroughly with KBr in 1:1 (sample: 
KBr) ratio, KBr discs were prepared by compressing the powders at a 
pressure of 5 tons for 5 min in a hydraulic press. Scans were obtained at 
a resolution of 4 cm–1 from 4000 to 400 cm–1. The IR spectra of the 
physical mixture of the topiramate and chitosan were compared with the 
spectrum of topiramate and chitosan to determine the compatibility of 
drug and excipient [24]. 
Differential Scanning Calorimetry (DSC) 
The thermal behavior of topiramate, chitosan, physical mixture of 
topiramate and chitosan and prepared topiramate nanoparticles 
was studied using differential scanning calorimetry (Mettler Toledo 
DSC 822e) at a rate of 10 °C min-¹ from 30° to 300 °C using a 
nitrogen purge of 50 ml/min [23]. 
X-ray diffraction studies (XRD) 
The crystallinities of topiramate, chitosan, physical mixture of 
topiramate and chitosan and prepared topiramate nanoparticles 
were analyzed by x-ray diffractometer (Bruker AXS D8 Advance 
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diffractometer) with a radius of 240 mm. The pattern was collected 
with 40 kV of tube voltage and 30 mA of tube current and scanned 
over the 2θ range of 3° to 80°. 
In vitro drug diffusion studies 
The drug diffusion characteristic was evaluated with the help of 
Franz diffusion cell with receptor capacity of 12.0 ml and 
permeation area of 3.14 cm2. A dialysis membrane (0.65 µm and 
mol. Wt. of 12000-14000) as a diffusion barrier was used in the 
donor compartment as a diffusion barrier. The membrane was 
equilibrated overnight before dispersing the formulation. The 
temperature of the receptor phase (pH 6.6 phosphate buffers) was 
maintained at 37±1 °C throughout the experiment by continuous 
stirring. Nanoparticles equivalent to 10 mg topiramate was placed in 
the donor compartment. 300 µl of the sample was withdrawn at a 
predetermined time interval from the receiver compartment and the 
same amount of fresh buffer solution was replaced to maintain the 
sink conditions. Each experiment was performed in triplicate and 
the sample was analyzed at a wavelength of 260 nm 
spectrophotometrically, taking phosphate buffer (pH 6.6) as a blank 
[23]. 
Kinetics and mechanism of drug release 
The data obtained from in vitro drug diffusion studies were plotted 
in various kinetic models: Zero-order, first-order, Higuchi’s model 
and Korsmeyer–Peppas model to study the release kinetics of 
optimized formulation. 
Ex-vivo permeation studies 
Ex vivo permeation study was performed for the optimized batch 
using freshly excised sheep nasal mucosa, as biomembrane 
obtained from the local slaughterhouse within 1h of sacrificing 
the animal. Nasal mucosa was carefully cut and mounted on the 
diffusion chamber with mucosal and serosal surfaces facing 
towards donor and receptor compartments, respectively. Other 
experimental procedures of sample collection and analysis were 
performed in the same way as in for in vitro diffusion studies 
[25]. 
Ex-vivo biocompatibility studies 
To determine the biocompatibility of prepared nanoparticles with 
nasal mucosa. histological study was carried out using freshly excised 
sheep nasal mucosa, thoroughly cleaned with isotonic saline solution. 
Prepared topiramate nanoparticles (100 mg) were applied properly 
on the nasal mucosa. After 1 h it was fixed in 10% neutral carbonate 
buffered formalin solution, routinely processed and embedded in 
paraffin. The experiment was carried out in a cell culture incubator 
(Sanyo Incubator, Model MCO-5AC, and Japan) to assure optimal 
conditions for the viability of the tissue. Further paraffin sections (7.5 
µm) were stained with Haematoxylin-Eosin (HE) indicator and 
observed under the Motic microscope. The untreated mucosa directly 
fixed after isolation was used as a control [26].  
RESULTS AND DISCUSSION 
Physicochemical characterization 
Particle size and zeta potential  
The percentage yield was calculated to determine the yield of 
nanoparticles obtained by the ionotropic gelation method. The results 
of percentage yield, drug content and entrapment efficiency are 
mentioned in table 2. All the batches of topiramate loaded chitosan 
nanoparticles showed a percentage yield from 72.02 to 83.73%. From 
the result, it was observed that as the concentration of chitosan was 
increased, an increase in percentage yield was observed. The particle 
size of nanoparticles varies with the concentration of chitosan used. At 
1% w/v chitosan concentration, the particles of nanoparticles were 
irregular with mean size 313.5 nm, which increase for nanoparticles 
prepared with chitosan, respectively. The topiramate loaded chitosan 
nanoparticles showed a decrease in particle size. The particle size of all 
the batches was in the range of 313.5 nm. As the volume of sodium 
tripolyphosphate was increased, a decrease in the particle size of 
nanoparticles was observed. 
  
Table 2: Percentage yield, average drug content and entrapment efficiency of mucoadhesive topiramate loaded chitosan nanoparticles 
Batch Percentage yield Drug content (%) Entrapment efficiency (%) 
F1 73.66 29.38±2.56 75.66±1.54 
F2 75.48 37.15±2.34 85.02±2.98 
F3 82.85 35.46±2.46 82.42±1.46 
F4 72.02 37.25±2.35 88.42±2.8 
F5 69.85 36.87±1.27 86.39±1.4 
F6 68.73 34.96±2.13 82.28±1.8 
F7 83.73 39.45±2.43 90.45±1.49 
F8 80.33 28.24±2.58 72.18±2.32 
Results are shown as mean±SD (n=3) 
 
 
Fig. 1: a. Zeta potential of topiramate loaded chitosan nanoparticles, b. zeta sizer 
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The zeta potential of topiramate and chitosan loaded nanoparticles 
were observed at -5.21 mv (fig. 1). It showed a negative charge. The 
formulation displayed negative zeta potential due to the 
introduction of reduction of droplets size on particles, which 
increases the anionic property of formulation this permanent 
negative charge carried by the protonated amino group of the 
formulation is driving force to the high solubility. 
Drug content and entrapment efficiency 
The resultant topiramate loaded chitosan nanoparticles had high 
drug content and high entrapment efficiency. As shown in table 2, 
the drug entrapment in the topiramate loaded chitosan 
nanoparticles was found to be increased with increased polymer: 
drug ratio. In general, formulations prepared by ionotropic gelation 
technique demonstrated considerably higher drug encapsulation 
efficiency. This is also evident from previous studies employing 
chitosan by the ionotropic gelation technique [27]. It is noteworthy 
that the F7 batch prepared with 275 mg of chitosan and 4% of STPP 
as a crosslinking agent showed the highest entrapment efficiency as 
90.45%. Thus, we have considered this formulation for further 
characterization and ex vivo evaluation. 
Scanning electron microscopy (SEM) 
The morphology of prepared nanoparticles was determined by SEM 
and photomicrographs of topiramate loaded chitosan nanoparticles 
are displayed in fig. 2. The surface morphology observed by the SEM 
showed the regular shape and smooth surface area of the prepared 
nanoparticles. The resultant nanoparticles did not show any 
ruptures on the surface, validating its rapid clearing from the nasal 
cavity with a good deposition pattern in the nasal cavity. 
  
 
Fig. 2: Scanning electron microscopy images of topiramate-loaded chitosan nanoparticles 
 
Ex-vivo bioadhesion studies 
The ex-vivo bioadhesion study was performed on F7 formulation 
using freshly excised sheep nasal mucosa. The prepared topiramate 
loaded chitosan nanoparticles showed high bioadhesion strength i.e. 
94.30%. The interaction between cationic groups on chitosan and 
anionic residues such as sialic acid and sulfonic acid on the nasal 
mucosa might have facilitated the strong adhesion of topiramate 
loaded chitosan nanoparticles on mucosal surfaces. This is speculated 
by several earlier findings employing chitosan as a polymer for the 
preparation of microsphere for nasal drug delivery system.  
Fourier-transform infrared spectroscopy (FTIR) 
The FTIR spectra of a mixture of topiramate and chitosan were 
compared with the spectra of pure chitosan and topiramate for the 
determination of interaction between drug and excipient. The 
spectrum of chitosan (fig. 3a.) was characterized by the presence of 
the band at 2890 cm−1 of C-H bonds. The band assigned to O-H 
(3000–3700 cm−1) on the chitosan spectrum. The vibration peak at 
3443 cm−1 was indicative of the O-H group. The characteristic bands 
at 1307 cm−1 and 1091 cm−1 on the chitosan spectrum indicated 
primary and secondary alcohols. The intense band cantered at 1664 
cm−1 on the chitosan spectrum is assigned to the C-O bonds of the 
acetamide groups, referred to as amide band. The obtained FTIR 
spectra also showed the same absorption peaks as mentioned above 
confirm the polymer was chitosan. The FTIR spectrum of topiramate 
(fig. 3b.) showed the characteristics peaks of absorption at 1072.47 
cm−1(S=0 Stretching), 1552.94 cm−1(N-H-stretching) and 1648.25 
cm−1(C=O stretching). All the absorption peaks are similar as 
observed in the reference spectra for the drug topiramate (I. P. 
2014). The spectrum of topiramate and chitosan physical mixture 
was characterized by the presence of strong absorption band 
absorption at 2956.48 cm−1(C-H Stretching), 1552.94 cm−1(N-H-
stretching) and 1648.25 cm−1(C=O stretching). The observation of 
the infrared spectroscopy (IR) spectra of the physical mixture of 
topiramate and polymer chitosan (fig. 3c.) showed all the major 
peaks of the topiramate, indicating that there was no interaction 
between the topiramate and chitosan. 
Differential scanning calorimetry 
Thermograms of pure topiramate, chitosan, physical mixture of 
chitosan and topiramate and topiramate-loaded chitosan 
nanoparticles were shown in fig. 4. DSC thermogram of topiramate 
illustrated sharp endothermic peak 126.24 °C, due to its melting 
point. Likewise, the DSC thermogram of chitosan exhibited a broad 
endothermic peak at 85.36 °C. By investigating the thermogram of 
topiramate loaded chitosan nanoparticles, (fig. 4d.) it was found that 
the endothermic peak corresponding to the melting point of 
topiramate was found to be reduced in intensity also seemed to be 
disappeared. This could be attributed to the incorporation and 
molecular dispersion of topiramate in chitosan polymer matrices of 
the prepared nanoparticle formulations. 
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Fig. 3: FTIR spectrum of a. chitosan, b. topiramate, c. a physical mixture of topiramate and chitosan, d. topiramate loaded chitosan nanoparticles 
 
 




Fig. 5: X-ray diffractogram of a. topiramate, b. chitosan, c. physical mixture of topiramate and chitosan, d. topiramate loaded chitosan 
nanoparticles 
 
X-ray diffraction studies  
The characteristic XRD spectra of pure topiramate, physical mixture of 
topiramate and chitosan and topiramate-loaded chitosan–nanoparticles 
were presented in fig. 5. Characteristic crystalline peaks of topiramate 
were observed in the pure drug sample reveals the presence of 
crystalline topiramate. Diffractogram of topiramate loaded chitosan 
nanoparticles (fig. 5d.) showed the disappearance of crystalline peaks 
indicating the amorphous form of drugs after its entrapment into 
chitosan nanoparticles prepared by ionotropic gelation method. 
In vitro drug diffusion studies  
The drug release profile of batch F1 to F8 was described in fig. 6. 
From the graph it was observed that an increase in the chitosan 
concentration significantly increases the the rate and extent of drug 
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release from nanoparticles. A maximum drug release was observed 
for F7 batch i.e. 94.19 % after 180 min. However, the Release of 
topiramate from the nanoparticles also changes with the 
crosslinking of the polymer. An increase in the amount of 
crosslinking agent reduces the drug release. So the rate of drug 
release from the nanoparticles prepared by the ionotropic gelation 
method can be modified by altering the concentration of chitosan 
and crosslinking agent sodium tripolyphosphate. 
 
 
Fig. 6: In vitro drug diffusion study of topiramate loaded chitosan nanoparticles (a: F1 to F4 and b: F5 to F8) 
 
Kinetics and mechanism of drug release 
Results of drug diffusion study of the F7 batch were fitted to kinetic 
models to investigate the kinetics of drug release (table 3). The 
optimized batch F7 was found to be best fitted in Higuchi kinetic 
model, as the plot showed highest linearity regression coefficient 
(R2) of 0.9980 compared to First-order (0.9807) and zero-order 
model (0.9945). The release data were also found to be best fitted to 
Peppas exponential model, to investigate the mechanism of drug 
release from nanoparticles formulation. The corresponding plot of 
the Korsmeyer-Peppas model indicated good linearity of regression 
coefficients (R2 = 0.9903). The release exponent (n) was found to be 
0.9131. The optimized F7 formulation followed the non-Fickian or 
anomalous diffusion mechanism of drug release when n>0.5. 
 
Table 3: Release kinetics of topiramate loaded chitosan nanoparticles 
Formulation code Zero-order (R) First order (R) Higuchi (R) Korsemeyer peppas (R) (n) 
F7 0.9945 0.9807 0.9980 0.9903 0.9131 
 
Ex-vivo permeation studies 
The ex–vivo permeation study was carried out for the optimized 
formulation i.e. F7 based on the results of the in vitro drug diffusion. 
The permeation of topiramate from nanoparticles of batch F7 was 
found to be 89.03% after 180 min as shown in fig. 7. Cationic 
bioadhesive polymeric material i.e., chitosan, can be used to enhance 
the drug dissolution and absorption through nanoparticles 
formulations of drugs for intranasal administration [28]. The 
Smaller particle size of nanoparticles provides the larger surface 
area and thus enhances the drug release from the formulations. 
Ex-vivo biocompatibility studies 
It is important to maintain nasal mucosal integrity while the 
preparation of nasal nanoparticles as repeated exposure may lead to 
the safety issue of the nasal membrane. The drug-loaded 
nanoparticles treated nasal mucosa did not show any deformity. The 
results of biocompatibility studies demonstrated that the prepared 
formulation as safe and biocompatible for intranasal administration. 
 
Fig. 7: Ex-vivo permeation of topiramate loaded chitosan 
nanoparticles of F7 batch 
 
 
Fig. 8: Histopathological specimen of A) untreated nasal mucosa, B) topiramate loaded chitosan nanoparticles treated nasal mucosa 
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CONCLUSION  
The present study demonstrated the successful formulation of 
mucoadhesive nanoparticles of topiramate by ionotropic gelation 
method. The formulation was characterized by percentage yield, 
entrapment efficiency, bioadhesion potential, ex vivo 
biocompatibility, in vitro drug diffusion profile and ex vivo drug 
permeation study. Physicochemical investigations demonstrated 
that the topiramate loaded nanoparticles showed the regular shape 
and smooth surface for nasal administration, high drug content and 
encapsulation efficacy and showed strong bioadhesion potential 
without any morphological toxicity to excised sheep nasal mucosa. 
Also, permeation across excised sheep nasal mucosa exhibited a 
good permeability of topiramate loaded chitosan nanoparticles. The 
results of biocompatibility study of topiramate loaded nanoparticles 
demonstrated that chitosan as safe and biocompatible polymers and 
can be applied to the nasal epithelium, which could be able to 
increase the absorption and bioavailability of the drug. Hence, the 
intranasal administration of topiramate nanoparticles can be 
considered as the better alternative for administration as compared 
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